Mapping of studies
The characteristics of the included studies are presented in Table 1. There has been a linear increase in the number of studies about treatment of CAPS over the past XX years (1996–2000, n = 8; 2011–2015, n = 50). Most studies were based in Europe (XX of XX), in particular the U.K. (XX of XX), Sweden (XX of XX), Germany (XX of XX) and Turkey (XX of XX) (Table 1 and Figure XX).
What is the evidence about the efficacy of the drugs that act on interleukin-1 in the treatment of CAPS?
What are the genetic and environmental factors associated with variability in response to the drugs that act on interleukin-1 in the treatment of CAPS?
1. Genetic factors
2. Environmental factors